Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in-person will be assigned to stand at their respective boards, organized by topic, on one of the three conference days. All posters will be available for viewing throughout the in-person conference in the poster hall and in an electronic format (access is restricted to registered CROI attendees during the conference).

Presenting Author Responsibilities

Creating a Poster

CROI poster presenting authors illustrate their study findings by displaying graphs, figures, diagrams, and text that describes their main findings, background, methods, results, and conclusions on posters that will be available virtually.

All poster presenters are required to create and upload an electronic poster. Posters should be designed to attract interested attendees by quickly focusing them on the main findings of the study. Poster presenters are encouraged to use the updated poster format, which can be accessed here: Updated Poster Format (Download). The slide notes contain poster guidelines that include formatting notes (eg, font size, use of color, poster print size) and poster content requirements (eg, poster number and no QR codes).

The electronic poster will need to be saved as a PDF file (not Word, PowerPoint, Image file).

Poster Title: The poster title should be the same as the title submitted with the abstract and appear in boldface at the top in either all capital letters or standard American Medical Association (AMA) title case. Nouns, pronouns, verbs, and other important words begin with uppercase letters; coordinating conjunctions, articles, and prepositions of 3 letters or fewer should all be in lowercase letters unless they are the first or last words in a title or subtitle.

Poster Number: The poster number should be displayed in the upper right corner (“0000” in the Alternate Poster Design template). This is not the abstract submission number assigned during submission of the abstract, but a number which denotes the position of the poster in the poster hall and in the conference program. This number will be sent to the presenting author after late-breaking abstracts have been accepted in January.

QR Codes and Links to External Materials Are Not Allowed: QR codes, bar codes, or other links to external resources are not permitted on posters displayed at CROI or on electronic versions of the posters to be uploaded to the CROI website.

Uploading Your Electronic Poster

Presenting authors should upload an electronic version of their poster prior to CROI. Submission details and deadline will be communicated after the January 5, 2023 submission deadline for all poster presenters.

Poster presenters are required to be at their poster during the session designated on the abstract disposition notice. If exigent circumstances preclude the presenting author from attending the session, a replacement must be found to present the poster.

Displaying Posters at CROI

The suggested size for posters is either 54 inches (width) x 36 inches (height) or 60 inches x 40 inches (137.2 cm x 91.4 cm or 152.4 cm x 101.6 cm) based on the CROI Poster Template. The minimum size for a poster is 36 inches (width) x 24 inches (height) so attendees can see the poster at a minimum of 10 feet away.The size of the board for displaying the poster is 96 inches (width) x 48 inches (height), and the maximum size of a poster is 93 inches (width) x 45 inches (height).

The face of the poster board is covered with Velcro-receptive fabric. Pushpins will be provided to hang posters.

Poster Printing

Presenting authors should print their physical poster based on the requirements listed in the sections above. CROI does not print posters on behalf of presenters.

Guidelines for Presentation

Trade Names

Trade names for drugs should not be used in abstracts. Refer to drugs and products by their nonproprietary names.

Statements of Support

Statements of grant support or funding statements may not be included in the abstract text (eg, Study was funded by NIH). Statements of support may be included in the presentation of the abstract at CROI, if accepted.

Sex Stratification and Other Demographic Variables

Abstracts from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. For human clinical or epidemiological studies, the presentation should provide sex-stratified results or identify who was included if it includes only a single population. Abstracts of preclinical data including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex (as assigned at birth) or gender (where gender is relevant to the study results), this should be identified as a limitation in the study.

See: ICMJE Preparing for Submission

Use of Appropriate Terminology

It is important to use  “people first” language such as “people with HIV” rather than “HIV-infected people.” Similarly, do not characterize people by their conditions. “People with diabetes” is preferred over “diabetics”; “patients with cirrhosis” rather than “cirrhotics;” “people who inject drugs” rather than ‘drug abusers.” Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.” Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors). Appropriate terminology such as “cisgender” (people whose gender matches the sex assigned at birth) or “transgender” (people whose gender does not match the sex assigned at birth) should be used.

Abstracts Describing New Compounds

Please be sure to include information sufficient to allow for meaningful review of compound data; this can include isolation, activity, chemical structure, mechanism of action, toxic effects, and pharmacologic data. The chemical or molecular structure must be shown in the presentation (it need not be part of the abstract or be published in the abstract eBook).

Case Reports and Systematic Reviews

In general, CROI does not accept abstracts for case reports, meta-analyses, or systematic reviews unless they are of enormous public health significance.

Publication or Presentation Prior to CROI

If study data are accepted for publication or presentation after the abstract submission to CROI, and that publication or presentation is expected to take place before CROI, the presenting author must contact CROI at CROIabstracts@iasusa.org to provide details as soon as the presentation is accepted for review, presentation, or publication in another venue or outlet. Please be aware that, although publication in these circumstances will not necessarily prevent presentation of the research at CROI, our strong preference is that any additional publication or presentation happen either simultaneous to or following presentation at CROI. Requests to publish or present research accepted for presentation at CROI prior to its presentation at CROI will be evaluated on a case-by-case basis. Failure to notify the conference promptly regarding plans to publish or present a CROI-accepted abstract prior to CROI may result in the removal of the study from the conference program.